Ovarian Cancer Coverage from Every Angle

Recent News

ESMO Asia 2020: SOLO1 Update on Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
Serous Ovarian Cancer: Paclitaxel Dosing Comparison From VELIA Trial
Chemoimmunotherapy Triplet Under Study in Recurrent Ovarian Cancer
Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer
Resensitization of Ovarian Cancer to Carboplatin Using Oncolytic Vaccine
Fixed Versus Individual Starting Dose of Niraparib in Advanced Ovarian Cancer
Novel TIE2 Kinase Inhibitor Under Study in Platinum-Resistant Ovarian Cancer
Use of Bevacizumab Beyond Disease Progression in Platinum-Resistant Ovarian Cancer
Maintenance Olaparib in Advanced Ovarian Cancer: SOLO-1 Long-Term Survival Update
Immunochemotherapy Primed With Oncolytic Vaccinia Virus in Platinum-Resistant Ovarian Cancer
ESMO 2020: Impact of Rising CA-125 Levels in Treating Platinum-Sensitive Recurrent Ovarian Cancer
Ongoing Study of Afuresertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
ESMO 2020: Maintenance Niraparib in Older Patients With Advanced Ovarian Cancer
ESMO 2020: Overall Survival With Weekly Dose-Dense Chemotherapy for Ovarian Cancer
IGCS 2020: Lenvatinib Plus Pembrolizumab in Ovarian Cancer
ESMO 2020: Novel PARP Inhibitor Under Study in Advanced Ovarian Cancer
IGCS 2020: Addition of Veliparib to Carboplatin Paclitaxel in Newly Diagnosed Ovarian Cancer
ESMO 2020: Olaparib Plus Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
IGCS 2020: Paclitaxel Plus Tumor-Treating Fields for Platinum-Resistant Ovarian Cancer
Does Shifting to Ultra-Radical Surgery Improve Outcomes in Advanced Epithelial Ovarian Cancer?
IGCS 2020: Maintenance Immunotherapy for Stage III or IV Ovarian Cancer
IGCS 2020: Biomarker Analyses From JAVELIN Ovarian 100 Trial
Incomplete Pregnancy and Risk of Invasive Ovarian Cancer
SGO Practice Statement: PARP Inhibitor Maintenance Therapy for Ovarian Cancer
Two-Step Surgical Approach to Ovarian Cancer Prevention: Survey of Premenopausal Women
Can a Prognostic Gene-Expression Signature Predict Survival in Ovarian Cancer?
Insomnia Impacts Many Women With Ovarian Cancer
Hormone Therapy Prior to Ovarian Cancer Diagnosis: Impact on Survival?
ASCO Guideline for Using PARP Inhibitors to Manage Ovarian Cancer
FDA Brief: Antibody XMT-1536 Receives Fast Track Designation for Ovarian Cancer
Novel Reversible LSD1 Inhibitor in Mutated Ovarian Cancer
New Tool May Aid in Identifying Subtypes of Ovarian Cancer
Targeted Therapy With Crizotinib for ROS1-Mutant Ovarian Cancer: Case Study
Novel First-in-Class Agent Shows Activity in High-Grade Serous Ovarian Cancer
NCI Funds Projects to Study Racial Disparities Among Women With Ovarian Cancer
Noninvasive Early Molecular Diagnosis of High-Grade Serous Epithelial Ovarian Cancer
Epithelial Ovarian Cancer: Risk Factors May Explain Racial Differences in Incidence
Novel ATR Inhibitor Under Study in Platinum-Resistant High-Grade Serous Ovarian Cancer
Ovarian Cancer and COVID-19: Challenges in Surgical Treatment
AACR II: Antibody-Drug Conjugate Targets CLDN6/9 in Epithelial Ovarian Cancer
AACR II: Synergistic Effects of Crizotinib and Olaparib in Ovarian Cancer
Study Assesses Risks Associated With Minimally Invasive Surgery for Early-Stage Ovarian Cancer
COVID-19 and Gynecologic Cancer: SGO Expert Panel Offers Clinical Considerations
BRCA-Mutated Ovarian Cancer and COVID-19: A Potential Alternative to Surgery
HIPEC Plus Secondary Cytoreductive Surgery for Resistant Ovarian Cancer
AACR II: Do Ovarian Cancer Survivors Have an Increased Risk for Type 2 Diabetes?
ASCO20: Is Quality of Life Shaped by Sleep Schedules in Ovarian Cancer Survivors?
AACR II: Lipophilic Statins and Ovarian Cancer Mortality
ASCO20: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
Hospital Case Load May Affect Survival in Ovarian Cancer
ASCO20: Autologous Tumor Immunotherapy Plus Atezolizumab in Recurrent Ovarian Cancer
ASCO20: Antibody-Drug Conjugate Plus Bevacizumab in Platinum-Agnostic Ovarian Cancer
ASCO20: Does Secondary Cytoreductive Surgery Offer Survival Benefit in Recurrent Ovarian Cancer?
ASCO20: Comparing Cediranib Regimens With Standard Chemotherapy in Recurrent Ovarian Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.